Cargando…
RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines
SIMPLE SUMMARY: To overcome some limitations of platinum-based chemotherapy agents, new active metallodrugs based on other transition metals are being researched. Runat-BI is a ruthenium-based compound which was synthesized and characterized at the University of Valencia. We investigated the in vitr...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817854/ https://www.ncbi.nlm.nih.gov/pubmed/36612065 http://dx.doi.org/10.3390/cancers15010069 |